Company intelligence / Profile preview
Tokai Pharmaceuticals
Boston, Massachusetts, United Statestokaipharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
Tokai’s lead candidate galeterone advanced through Phase 2 and into a pivotal Phase 3 trial for AR-V7 positive mCRPC but failed to meet its primary endpoint in the ARMOR3-SV study. The company discontinued the trial after interim analysis showed it would likely not succeed. Some exploratory studies continued in other resistant patient populations, but the main clinical program did not progress to approval or commercialization.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Novartis Venture Funds participated as an investor; no major disclosed pharma development partnerships found beyond investors/funders
Beyond the preview
Go deeper on Tokai Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tokai Pharmaceuticals.